Craig Johnstone

发表

Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.

D. Mckerrecher, C. Johnstone, Craig S Donald, 2011, Bioorganic & medicinal chemistry letters.

Discovery, synthesis and biological evaluation of novel glucokinase activators.

Scott Boyd, G. Currie, B. Hayter, 2005, Bioorganic & medicinal chemistry letters.

Creativity, innovation and lean sigma: a controversial combination?

Garry Pairaudeau, G. Pairaudeau, Jonas A Pettersson, 2011, Drug discovery today.

Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092

Michael J. Waring, Graeme R. Robb, M. Waring, 2011 .

Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656

Michael J. Waring, Graeme R. Robb, David S. Clarke, 2012 .

Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators

Michael J. Waring, Graeme R. Robb, Craig Johnstone, 2011 .

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

S. Wedge, J. Kendrew, Andrew P Thomas, 2002, Journal of medicinal chemistry.

Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.

Craig S Donald, Kurt G Pike, Joanne V Allen, 2006, Bioorganic & medicinal chemistry letters.

Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality.

Nidhal Selmi, Jan Kihlberg, Magnus J. Johansson, 2009, Drug discovery today.